Impact Biomedical (IBO) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
IMPACT BIOMEDICAL INC.  (NYSE: IBO)


Impact Biomedical's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Impact Biomedical's ROA in the third quarter of 2026?
IMPACT BIOMEDICAL INC. achieved a return on average assets (ROA) of 8.7 % in its third quarter of 2026, this is above IBO's average return on assets of -72.37%.
Impact Biomedical Inc. assets over the 12 months ending in its third quarter of 2026 are valued at $18 million

ROA has improved compared to 4.1% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector IMPACT BIOMEDICAL INC. achieved the highest return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 4162, from total ROA ranking in the second quarter of 2026 at 4765.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Total Assets Change -9.76 % -12.04 % -14.69 % -54.11 % -60.7 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 2 1 -13 -12 -44
Return On Assets (TTM) 8.7 % 4.1 % -66.04 % -58.64 % -163.64 %
IBO's Total Ranking # 4162 # 4765 # 4664 # 4621 # 4422
Total Assets (TTM) in million 17 17 17 23 18
Seq. Total Assets Change -1.95 % -1.98 % -24.96 % 25.12 % -4.42 %
Seq. Net Income Change - - - - -

IBO's 5 Years Annual ROA >> Back to IBO Management Effectiveness >> Compare IBO ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 0
Sector # 0
Overall # 0

Return On Assets Statistics
High Average Low
4.47 %
-72.37 %
-227.98 %
(Jun 30 2026)   (Sep 30 2025)





Financial Statements
Impact Biomedical's Assets $ 17 million IBO's Balance sheet
Impact Biomedical's Income $ -1 million Quarterly IBO's Income Statement
IBO's Income by Division See IBO's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2022)
FY 2023
FY
FY
Y / Y Total Assets Change -54.11 % -4.46 % - - -
Total Assets in million 23 50 53 0 0
Y / Y Net Income Change - - - - -
Net Income in million -12 -25 -7 0 0
Annual Return On Assets -51.53 % -49.35 % -13.42 % - -

IBO's 5 Years Annual ROA >> Back to IBO Management Effectiveness >> Compare IBO ROA to its Competitors



More Return On Assets Ratios
IBO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IBO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IBO's Competitors
Subscribers only: Roa for Impact Biomedical's Suppliers
Subscribers only: Return On Assets for IBO's Customers

You may also want to know
IBO's Roi IBO's Inventory Turnover Ratio IBO's Growth Rates IBO's Dividend Comparisons
IBO's Profitability Ratios IBO's Asset Turnover Ratio IBO's Dividend Growth
IBO's Roe IBO's Valuation Ratios IBO's Financial Strength Ratios IBO's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Acadia Pharmaceuticals Inc   21.60 %
Standard Biotools Inc   21.56 %
Eli Lilly And Company  21.24 %
Iradimed Corporation  20.89 %
Resmed Inc   18.67 %
Alector Inc   18.37 %
Corcept Therapeutics Inc  18.09 %
Chemed Corporation  17.73 %
Halozyme Therapeutics Inc   17.26 %
Pro dex Inc   16.75 %
Denali Therapeutics Inc   16.42 %
Krystal Biotech Inc   15.48 %
West Pharmaceutical Services Inc   15.47 %
Dexcom Inc   15.47 %
Intuitive Surgical Inc   14.71 %
Vertex Pharmaceuticals Inc  14.16 %
Neurocrine Biosciences Inc   13.69 %
Illumina Inc   13.43 %
Healthcare Services Group Inc   12.79 %
Kiniksa Pharmaceuticals International Plc  12.64 %
Tenet Healthcare Corp  12.39 %
Hca Healthcare Inc   11.73 %
Carlisle Companies Incorporated  11.72 %
Regeneron Pharmaceuticals Inc   11.50 %
Lantheus Holdings Inc   11.43 %
Msa Safety Inc  11.01 %
Encompass Health Corporation  10.99 %
Inspire Medical Systems inc   10.89 %
Transmedics Group Inc   10.67 %
Bristol myers Squibb Company  10.47 %

Date modified: 2026-11-10T10:03:31+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.